BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 10404830)

  • 1. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
    Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
    Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
    J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New perspectives in medical management of hyperprolactinemia.
    Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Sileo F; Ferrari L; Stroppa S; Gualteroni L; Pagani G
    Endocrinol Exp; 1990 Mar; 24(1-2):159-66. PubMed ID: 2361458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
    N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
    J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
    Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
    Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
    J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
    Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
    Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
    Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
    Motta T; de Vincentiis S; Marchini M; Colombo N; D'Alberton A
    Fertil Steril; 1996 Feb; 65(2):440-2. PubMed ID: 8566276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
    De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
    Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.